PBM Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Psyence Biomedical Ltd | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerPBM

Market Cap1.3M

Cash RunwayUnknown

Next Catalyst2026-12-30

Public Research Snapshot

Psyence Biomedical Ltd is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Psilocybin therapy (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Psilocybin therapy	n/a	n/a	Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2026-12-30	Psilocybin therapy	Low

Cash Runway Preview

Estimated cash runway: Unknown.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT07072728	Phase 2	RECRUITING	87	2026-12-30

Scientific Context

literature_publication | Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones.
asset_name | Psilocybin therapy
catalyst_date_estimated | 2026-12-30
catalyst_type | Clinical Trial Completion
clinical_stage | Phase 2

Want the full PBM research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.